Nuritas, a trailblazer in the intersection of life sciences and artificial intelligence, is thrilled to announce that it has successfully raised $42 million in its latest funding round. This impressive investment will bolster the company's groundbreaking work in peptide discovery and development, facilitated by its proprietary Nuritas MagnifierNπΦ platform. This innovative technology not only identifies and unlocks bioactive peptides but also ensures they are clinically tested and patented, allowing for their transformation into powerful ingredients that can enhance the efficacy of everyday products. The funds will primarily focus on scaling operations and continuing to advance research efforts aimed at harnessing nature's wisdom to create healthier, greener, and safer alternatives for consumers. Nuritas is dedicated to empowering individuals to lead healthier lives through the integration of these advanced ingredients into the food and personal care sectors. With a vision of improving the well-being of billions, the company is excited to translate its groundbreaking discoveries into tangible innovations that elevate the quality of life. As Nuritas continues to push the boundaries of what is possible in natural health solutions, this funding marks a significant milestone towards realizing its mission of making natural living not only achievable but also increasingly efficacious.
Nuritas Secures $42M Funding for Revolutionizing Natural Health Innovation
Get the full Nuritas company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Texas Automated Robotics Systems, LLC
Tars Robotics, based in Houston Texas, strives to equip manufacturers with the highest quality robotic automation equipment at the most economical value in the industry. Our goal is to enable as many American manufacturers with the ability to compete in the global injection molding industry. We continue to support the initiative to re-shore products from all industries back to the United States. We offer a wide and unique line of robotic arms for machines ranging from 30 tons to 4,000 tons while providing the best solutions no matter how intelligible or complex. With our customer’s need in mind, our product lines include a diverse series of robots designed for sprue and parts removal, insert molding, de-gating, in-mold labeling, and parts stacking.
$513.0M Seed
today
Viseur AI - Digital Pathology Platform
Viseur AI is a digital pathology and medical imaging platform built to become the operating system of AI-enabled diagnostics. We unify Pathology Information Management (PIMS), Digital Pathology / WSI viewing (IMS), AI model deployment and governance, and enterprise-grade integrations into a single, vendor-agnostic platform designed for real clinical workflows. Healthcare systems and diagnostic labs struggle with fragmented pathology workflows, scanner-locked software, and AI solutions that rarely reach routine clinical use. Viseur AI addresses this by delivering an end-to-end digital pathology platform from specimen to report, combining enterprise-grade WSI viewing, AI model deployment and management, on-prem or hybrid architectures aligned with data privacy and regulatory requirements, and deep LIS, HIS, and PACS integrations that enable standardised and scalable operations across multiple sites. Certified under ISO 13485, ISO 27001, and ISO/IEC 15504-SPICE, Viseur AI creates a foundation for clear and compatible AI in healthcare.
$350.0K Seed
today
Imperagen
Imperagen is advancing enzyme engineering through an integrated, AI-driven platform that enables faster and more precise development of high-performance enzymes. By combining advanced computational modeling with automated lab testing, we help companies improve production processes while reducing cost, time, and environmental impact. Founded by researchers from the Manchester Institute of Biotechnology, Imperagen brings together expertise in physics-based simulation, machine learning, and high-throughput experimentation. Our closed-loop platform continuously learns from real-world data, allowing us to design, test, and refine enzymes with greater accuracy and efficiency than traditional approaches . We take a problem-specific approach, tailoring each solution to the unique requirements of a given enzyme, reaction, and application. We work with organizations across pharma, life sciences, chemicals, food, and consumer goods to solve complex enzyme engineering challenges. Our approach helps reduce development risk, shorten timelines, and support the shift toward more sustainable, enzyme-based manufacturing. Get in touch to learn more about our innovative platform and discover how we can quickly transform your enzyme needs into market-ready solutions.
$6.4M Seed
today
Omni
Omni is an AI analytics platform that empowers everyone—regardless of technical ability—to easily analyze data using AI, spreadsheets, SQL, or point-and-click interfaces. It is built on a semantic layer that makes sure every insight is accurate and dependable. Beyond powering internal analytics, Omni makes it easy for businesses to offer highly customizable in-product analytics to their customers.
$120.0M Series c
today
Moment
The largest RIAs, broker dealers, and private banks trust Moment to power investment management for their traders and advisors. Founded by former fixed income quants from Citadel and Jane Street and backed by over $50M in funding from the world’s leading investors, Moment has developed the first operating system built specifically for wealth management. With Moment’s solution, advisors can build personalized portfolios in seconds, traders can set rules to automatically execute orders at all of the major trading venues, and portfolio managers can automate reinvestment, rebalancing, and compliance monitoring. Moment is headquartered in the Financial District of New York City. Learn more below and follow the team’s rapid growth here on LinkedIn.
$78.0M Series c
today